<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04719637</url>
  </required_header>
  <id_info>
    <org_study_id>RDN-19-001</org_study_id>
    <nct_id>NCT04719637</nct_id>
  </id_info>
  <brief_title>Clinical Study of an Ultrasound Renal Denervation System in Patients With Heart Failure</brief_title>
  <official_title>Clinical Study of an Ultrasound Renal Denervation System in Patients With Heart Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Otsuka Medical Devices Co., Ltd. Japan</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Otsuka Medical Devices Co., Ltd. Japan</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose is to evaluate the renal denervation system (PRDS-001) for controlling&#xD;
      sympathetic nerve over-activation in patients with heart failure, and for its safety in such&#xD;
      patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 24, 2021</start_date>
  <completion_date type="Anticipated">November 2025</completion_date>
  <primary_completion_date type="Anticipated">June 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>MIBG-cardiac(washout rate)</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>MIBG-cardiac(early; heart-to-mediastinum ratio (H/M), late: H/M)</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anaerobic Threshold assessed by CPX (Cardiopulmonary Exercise Testing)</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lowest minute ventilation (VE)/carbon dioxide output (VCO2) assessed by CPX</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak oxygen uptake (peak VO2) assessed by CPX</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak VO2/heart rate assessed by CPX</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VE-VCO2 slope assessed by CPX</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak respiratory exchange ratio assessed by CPX</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak load assessed by CPX</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ramp duration assessed by CPX</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary noradrenalin concentration</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NYHA class</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MIBG-renal (washout rate)</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MIBG-renal (early: kidney-to-mediastinum ratio (K/M), late: K/M)</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Chronic Heart Failure</condition>
  <arm_group>
    <arm_group_label>PRDS-001</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Renal denervation</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>PRDS-001 Renal Denervation Ultrasound System</intervention_name>
    <description>Renal Denervation Ultrasound System</description>
    <arm_group_label>PRDS-001</arm_group_label>
    <other_name>renal denervation</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria :&#xD;
&#xD;
          -  Patients aged 18 years or older and younger than 85 years at the time of informed&#xD;
             consent&#xD;
&#xD;
          -  NYHA (New York Heart Association) class II-III&#xD;
&#xD;
          -  More than 6 weeks have passed since onset of acute heart failure or acute exacerbation&#xD;
             of chronic heart failure&#xD;
&#xD;
          -  Washout rate of MIBG [3 (meta)-iodobenzylguanidine] scintigraphy-cardiac is more than&#xD;
             35%&#xD;
&#xD;
          -  Patients having continued treatment of heart failure with the same dosage and&#xD;
             administration for 4 weeks before obtaining informed consent&#xD;
&#xD;
        Exclusion Criteria :&#xD;
&#xD;
          -  Patients with type1 diabetes mellitus, or uncontrolled type 2 diabetes mellitus&#xD;
             (HbA1c: â‰¥ 8%)&#xD;
&#xD;
          -  Patients whose eGFR (estimated glomerular filtration rate) is less than 40 mL/min/1.73&#xD;
             m^2 (estimation formula by Japanese Society of Nephrology)&#xD;
&#xD;
          -  Patients with concomitant or previous autoimmune or inflammatory bowel disease&#xD;
&#xD;
          -  Patients with a history of serious lung disease&#xD;
&#xD;
          -  Patients with a history of heart transplantation or VAD [ventricle-assist device]&#xD;
&#xD;
          -  Patients receiving reserpine, tricyclic antidepressants, and labetalol hydrochloride&#xD;
             (can be used for up to 5 half-lives before informed consent is obtained)&#xD;
&#xD;
          -  Patients being treated for Parkinson's disease or Lewy body dementia&#xD;
&#xD;
          -  Patients with a history of any severe cardiovascular event (myocardial infarction,&#xD;
             coronary artery bypass graft surgery, acute heart failure requiring hospitalization)&#xD;
             or severe cerebrovascular event (stroke, transient ischemic event, cerebrovascular&#xD;
             accident, etc.) within 3 months before obtaining informed consent&#xD;
&#xD;
          -  Patients with persistent atrial fibrillation&#xD;
&#xD;
          -  Patients using active implantable medical devices&#xD;
&#xD;
          -  Patients with coronary or carotid artery diseases who were deemed necessary by the&#xD;
             principal investigator / sub investigator to undergo surgery or PCI (Percutaneous&#xD;
             Coronary Intervention) within 6 months after obtaining informed consent&#xD;
&#xD;
          -  Patients with contraindications, unacceptable anaphylactic reactions, or&#xD;
             uncontrollable allergies to contrast media&#xD;
&#xD;
          -  Female patients who are pregnant or breastfeeding&#xD;
&#xD;
          -  Patients whose office blood pressure (systolic) is 100mmHg or lower at the time of&#xD;
             screening test&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>84 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Mikiko Haraguchi</last_name>
    <phone>+81-3-6361-7459</phone>
    <email>OtsukaRegistry-CT@otsuka.jp</email>
  </overall_contact>
  <location>
    <facility>
      <name>Osaka University Hospital</name>
      <address>
        <city>Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>December 16, 2020</study_first_submitted>
  <study_first_submitted_qc>January 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 22, 2021</study_first_posted>
  <last_update_submitted>October 4, 2021</last_update_submitted>
  <last_update_submitted_qc>October 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Denervation</keyword>
  <keyword>Renal denervation</keyword>
  <keyword>Heart failure</keyword>
  <keyword>Ultrasound</keyword>
  <keyword>Cardiovascular Diseases</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

